Top

Published in:

Open Access 01-12-2022 | Filgrastim | Original Research Article

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study

Authors: Abeer A. Al-Rabayah, Ola Al Mashni, Esraa Hanoun, Weam Al Qasem, Deema Al Momani, Rawan Fawzi Al Froukh, Razan Sawalha, Suzan S. Hammoudeh

Published in: Drugs - Real World Outcomes | Issue 4/2022

Abstract

Background

Despite the demonstrated efficacy and safety of biosimilar filgrastim-aafi (Nivestim™), few studies have compared its use in real-life clinical practice to the originator filgrastim (Neupogen™).

Objectives

This study aimed to compare the effectiveness and safety of filgrastim and filgrastim-aafi for the primary prophylaxis of chemotherapy induced-febrile neutropenia in the real-life setting.

Patients and methods

A retrospective cohort study included all adult cancer patients at the King Hussein Cancer Centre requiring primary prophylaxis for chemotherapy-induced febrile neutropenia between 2014 and 2016. Two cohorts were selected: patients who received filgrastim and those who received filgrastim-aafi. The primary endpoint was the incidence of febrile neutropenia; the secondary endpoints were the incidence of adverse drug reactions (ADRs), hospital admissions due to febrile neutropenia, and the mean length of hospitalization. Chi-squared tests were performed to evaluate differences between groups. Logistic regression was conducted to adjust for confounding factors.

Results

A total of 268 patients were identified, with 88 in the filgrastim cohort and 180 in the filgrastim-aafi cohort; 64%were females. The mean age was 47 (±15) years. The incidence of febrile neutropenia was 21.6% in the filgrastim cohort and 15% in the filgrastim-aafi cohort (P = 0.179). No statistically significant differences were detected in the incidence of hospital admission (P = 0.551) or ADRs (P = 0.623) between the two cohorts. Upon adjusting for the confounding factors, results remained statistically insignificant.

Conclusion

Filgrastim and filgrastim-aafi had comparable effectiveness and safety as primary prophylaxis for chemotherapy-induced febrile neutropenia. More extensive prospective studies with additional insight on the cost implications are required.

Available only for authorised users

Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, et al. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: a systematic review. J Oncol Pharm Pract. 2016;22(5):702–16.CrossRefPubMed

Liu Z, Doan QV, Malin J, Leonard R. The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy. 2009;7(3):193–205.CrossRefPubMed

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(Suppl_5):v111–8.CrossRefPubMed

Price TH, Chatta GS, Dale DC. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood. 1996;88:335–40.CrossRefPubMed

Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3–4 week chemotherapy regimens in community oncology practices. J Manag Care Pharm. 2007;13(4):337–48.CrossRefPubMed

Rapoport BL, Aapro M, Paesmans M, van Eeden R, Smit T, Krendyukov A, et al. Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational. BMC Cancer. 2018;18(1):917.CrossRefPubMedPubMedCentral

de Mora F. Biosimilars: a value proposition. BioDrugs. 2019;33(4):353–6. https://doi.org/10.1007/s40259-019-00360-7.CrossRefPubMed

Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. J Natl Compr Canc Netw. 2015;13(1):e1–7.CrossRefPubMed

Cornes P, Krendyukov A. The evolution of value with filgrastim in oncology. Future Oncol. 2019;15(13):1525–33. https://doi.org/10.2217/fon-2018-0762.CrossRefPubMed

10.

Declerck P, Danesi R, Petersel D, Jacobs I. The language of biosimilars: clarification, definitions, and regulatory aspects. Drugs. 2017;77(6):671–7. https://doi.org/10.1007/s40265-017-0717-1.CrossRefPubMedPubMedCentral

11.

Hospira. Nivestym (filgrastim) [package insert]. Washington DC: US Food and Drug Administration; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761080s000lbl.pdf. Accessed 16 Jun 2019.

12.

Hospira. Nivestim (filgrastim) [package insert]. London: European Medicines Agency; 2019. www.ema.europa.eu/en/documents/product-information/nivestim-epar-product-information_en.pdf. Accessed 16 Jun 2019.

13.

Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Oncol Res Treat. 2010;33(10):504–11.CrossRef

14.

Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89(9):927–33.CrossRefPubMedPubMedCentral

15.

Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol. 2010;89(10):971–8.CrossRefPubMedPubMedCentral

16.

Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, LaVange L, Marinac-Dabic D, Marks PW, Robb MA, Shuren J, Temple R, Woodcock J, Yue LQ, Califf RM. Real-world evidence—what is it and what can it tell us? N Engl J Med. 2016;375(23):2293–7. https://doi.org/10.1056/NEJMsb1609216.CrossRefPubMed

17.

Nahon S, Rastkhah M, Ben Abdelghani M, Soumoudronga RF, Gasnereau I, Labourey JL. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. Support Care Cancer. 2016;24(5):1991–8.CrossRefPubMed

18.

Douglas AG, Schwab P, Lane D, Kennedy K, Slabaugh SL, Bowe A. A comparison of brand and biosimilar granulocyte-colony stimulating factors for prophylaxis of chemotherapy-induced febrile neutropenia. J Manage Care Spec Pharm. 2017;23(12):1221–6.CrossRef

19.

Damaj GL, Benbrahim O, Hacini M, Voronina I, Benabed K, Soumoudronga RF, et al. ZOHé: a prospective study of the use of biosimilar filgrastim Zarzio in clinical practice in patients treated with chemotherapy for lymphoid malignancies. Clin Lymphoma Myeloma Leuk. 2017;17(6):362–9.CrossRefPubMed

20.

Schwartzberg LS, Lal LS, Balu S, Campbell K, Brekke L, Elliott C, et al. incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar. Clinicoecon Outcomes Res. 2018;10:493–500.CrossRefPubMedPubMedCentral

21.

Yao HM, Ottery FD, Borema T, et al. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen®): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. BioDrugs. 2019;33:207–20. https://doi.org/10.1007/s40259-019-00343-8.CrossRefPubMedPubMedCentral

22.

Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007;25(21):3158–67.CrossRefPubMed

23.

Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: a systematic review and meta-analysis. BMC Cancer. 2011;11:404.CrossRefPubMedPubMedCentral

24.

Brito M, Esteves S, André R, Isidoro M, Moreira A. Comparison of effectiveness of biosimilar filgrastim (NivestimTM), reference Amgen filgrastim and pegfilgrastim in febrile neutropenia primary prevention in breast cancer patients treated with neo(adjuvant) TAC: a non-interventional cohort study. Support Care Cancer. 2016;24(2):597–603.CrossRefPubMed

25.

Fruehauf S, Otremba B, Stötzer O, Rudolph C. Compatibility of biosimilar filgrastim with cytotoxic chemotherapy during the treatment of malignant diseases (VENICE): a prospective, multicenter, non-interventional, longitudinal study. Adv Ther. 2016;33(11):1983–2000.CrossRefPubMedPubMedCentral

26.

Kamioner D, Fruehauf S, Maloisel F, Cals L, Lepretre S, Berthou C. Study design: two long-term observational studies of the biosimilar filgrastim NivestimTM (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. BMC Cancer. 2013;13(1):547.CrossRefPubMedPubMedCentral

27.

Lathia N, Mittmann N, DeAngelis C, Knowles S, Cheung M, Piliotis E, et al. Evaluation of direct medical costs of hospitalization for febrile neutropenia. Cancer. 2010;116(3):742–8.CrossRefPubMed

28.

Dulisse B, Li X, Gayle JA, Barron RL, Ernst FR, Rothman KJ, et al. A retrospective study of the clinical and economic burden during hospitalizations among cancer patients with febrile neutropenia. J Med Econ. 2013;16(6):720–35.CrossRefPubMed

29.

Lal A, Bhurgri Y, Rizvi N, Virwani M, Memon RU, Saeed W, et al. Factors influencing in-hospital length of stay and mortality in cancer patients suffering from febrile neutropenia. Asian Pac J Cancer Prev. 2008;9(2):303–8.PubMed

30.

Schelenz S, Giles D, Abdallah S. Epidemiology, management and economic impact of febrile neutropenia in oncology patients receiving routine care at a regional UK cancer centre. Ann Oncol. 2012;23(7):1889–93.CrossRefPubMed

31.

Leese B. The costs of treating febrile neutropenia in six UK hospitals. Eur J Cancer. 1993;29A(Suppl):S15–8.CrossRef

32.

Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106(10):2258–66.CrossRefPubMed

33.

Kawatkar AA, Farias AJ, Chao C, Chen W, Barron R, Vogl FD, et al. Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer. 2017;25(9):2787–95.CrossRefPubMedPubMedCentral

34.

Weycker D, Barron R, Kartashov A, Legg J, Lyman GH. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20(3):190–8.CrossRefPubMed

35.

Li S, Liu J, Bowers C, Garawin TAFS, Kim C, Bensink ME, et al. Febrile neutropenia-related care and associated costs in elderly patients with breast cancer, lung cancer, or non-Hodgkin lymphoma. Support Care Cancer. 2019. https://doi.org/10.1007/s00520-019-04795-0.CrossRefPubMedPubMedCentral

36.

Olmos A, Govindasamy P (2015) A Practical Guide for Using Propensity Score Weighting in R. PracticalAssessment, Research & Evaluation, 20(13). http://pareonline.net/getvn.asp?v=20&n=13

37.

Klastersky J, de Naurois J, Rolston K, Rapoport B, Maschmeyer G, Aapro M, Herrstedt J, ESMO Guidelines Committee. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111–8. https://doi.org/10.1093/annonc/mdw325.CrossRefPubMed

38.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncoloy.Hematopoietic Growth Factors Version 4.2021. Fort Washington (PA): National Comprehensive Cancer Network; 2021. https://www.nccn.org/professionals/physician_gls/pdf/growthfactors.pdf.

39.

Cornes P, Gascon P, Vulto AG, Aapro M. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs. 2020;34(3):255–63. https://doi.org/10.1007/s40259-020-00411-4.CrossRefPubMedPubMedCentral

40.

Cornes P, Gascon P, Chan S, et al. Systematic review and meta-analysis of short- versus long-acting granulocyte colony-stimulating factors for reduction of chemotherapy-induced febrile neutropenia. Adv Ther. 2018;35(11):1816–29. https://doi.org/10.1007/s12325-018-0798-6.CrossRefPubMedPubMedCentral

Title: Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
Authors: Abeer A. Al-Rabayah
Ola Al Mashni
Esraa Hanoun
Weam Al Qasem
Deema Al Momani
Rawan Fawzi Al Froukh
Razan Sawalha
Suzan S. Hammoudeh
Publication date: 01-12-2022
Publisher: Springer International Publishing
Keywords: Filgrastim
Neutropenia
Filgrastim
Cytostatic Therapy
Published in: Drugs - Real World Outcomes / Issue 4/2022
Print ISSN: 2199-1154
Electronic ISSN: 2198-9788
DOI: https://doi.org/10.1007/s40801-022-00312-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study

Abstract

Background

Objectives

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Objectives

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4/2022

Factors Associated with Discontinuation of Statin Therapy in Patients with Lymphoma Aged 80 Years and Older: A Retrospective Single-Institute Study

Retrospective Cohort Evaluating the Comparative Effectiveness of Ceftaroline and Daptomycin as First-Line Therapies for Inpatient Treatment of Diabetic Foot Infection in the United States Veterans Health Care System

Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database

Drug-Induced QT Prolongation and Torsade de Pointes in Spontaneous Adverse Event Reporting: A Retrospective Analysis Using the Japanese Adverse Drug Event Report Database (2004–2021)

Real-World Patient Characteristics, Utilization Patterns, and Outcomes of US Patients with HR+, HER2− Metastatic Breast Cancer Treated with Abemaciclib

A Review of Research Studies Using Data from the Administrative Claims Databases in Japan